雷帕鸣在治疗肾移植这方面的效果如何？

As an immunosuppressant, rapamycin (sirolimus tablets) is different from commonly used immunosuppressants such as cyclosporine and tacrolimus. It has the ability to inhibit the growth of hepatocellular carcinoma cells. This ability has been confirmed in in vivo and in vitro experiments.

So, how effective is Rapamin in the treatment of kidney transplantation?

In order to verify the effectiveness and safety of sirolimus in conversion therapy for kidney transplant recipients, a domestic experiment conducted a sirolimus-based conversion therapy on 50 recipients who were mainly taking oral calcineurin inhibitors after allogeneic kidney transplantation. Among them, there were 29 males and 21 females, aged (40±13) years old; 7 patients had calcineurin inhibitor hepatotoxicity, 8 patients had post-transplantation diabetes, 27 cases had chronic allograft nephropathy, and 8 patients had post-transplantation complications of tumors. The treatment plan for all patients adopts a rapid conversion method, with a single first loading dose of 6 mg, followed by a maintenance dose of 2 mg/d. The dose will be adjusted based on the plasma concentration of sirolimus to maintain the trough plasma concentration at 6 to 10 μg/L. Dynamically observe the blood creatinine level and the incidence of acute rejection after sirolimus conversion, and monitor blood routine, blood sugar, blood lipids, liver function and other indicators, and observe the clinical effects, safety and adverse reactions within 6 months after conversion.

The final study results showed that the incidence of acute rejection within 6 months after sirolimus conversion was 10.1%; recipients who underwent drug conversion due to chronic transplant kidney disease had significantly improved renal function after conversion; other original liver damage and hyperglycemia were mostly improved after conversion; 8 tumor recipients had stable conditions without recurrence within 6 months after conversion. Adverse reactions mainly include hyperlipidemia and proteinuria.

Finally, the study concluded: After kidney transplant recipients taking calcineurin inhibitors develop one or more risk factors, switching to rapamycin is a better choice, as it is safe, effective and has few adverse reactions. In this regard, patients can purchase and use it with confidence.